Prognostic information of serial plasma osteopontin measurement in radiotherapy of non-small-cell lung cancer

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Ostheimer, Christian ^a   Bache, Matthias ^a   Guttler, Antje ^a   Reese, Thomas ^a   Vordermark, Dirk ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Non small cell lung cancer; Osteopontin; Plasma biomarker; Prognostic factors; Radiotherapy; Tumor hypoxia

Indexed keywords

CISPLATIN; HEMOGLOBIN; NAVELBINE; OSTEOPONTIN; BIOLOGICAL MARKER;

ADULT; ARTICLE; BLOOD LEVEL; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPLORATORY RESEARCH; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PATIENT MONITORING; PROSPECTIVE STUDY; TUMOR VOLUME; WEIGHT REDUCTION; AGED; BLOOD; CANCER GRADING; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS; MORTALITY; PATHOLOGY; PROGNOSIS; RISK FACTOR; TREATMENT OUTCOME;

ADULT; AGED; BIOMARKERS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; OSTEOPONTIN; PROGNOSIS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84964312402     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-858     Document Type: Article

References (34)

1. Semrau S, Bier A, Thierbach U, Virchow C, Ketterer P, Klautke G, Fietkau R: 6-year experience of concurrent radiochemotherapy with vinorelbine plus a platin compound in multimorbid or aged patients with inoperable non-small cell lung cancer. Strahlenther Onkol 2007, 1:30-35.
2. Vaupel P, Mayer A: Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007, 26:225-239.
3. Nordsmark M, Bentzen SM, Rudat V, Brizel D, Lartigau E, Stadler P, Becker A, Adam M, Molls M, Dunst J, Terris DJ, Overgaard J: Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 2005, 77:18-24.
4. Le QT: Identification and targeting hypoxia in head and neck cancer-a brief overview of current approaches. Int J Radiat Oncol Biol Phys 2007, 69:S56-S58.
5. Bache M, Kappler M, Said HM, Staab A, Vordermark D: Detection and specific targeting of hypoxic regions within solid tumors: current preclinical and clinical strategies. Curr Med Chem 2008, 15:322-338.
6. Le QT, Courter D: Clinical biomarkers for hypoxia targeting. Cancer Met Rev 2008, 27:351-362.
7. Vordermark D, Brown JM: Endogenous markers of tumor hypoxia. Strahlenther Onkol 2003, 179:801-811.
8. Le QT, Chen E, Salim A, Cao H, Kong CS, Whyte R, Donington J, Cannon W, Wakelee H, Tibshirani R, Mitchell JD, Richardson D, O'Byrne KJ, Koong AC, Giaccia AJ: An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin Cancer Res 2006, 12:1507-1514.
9. Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF, Yeatman TJ: Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 2004, 10:184-190.
10. Isa S, Kawaguchi T, Teramukai S, Minato K, Ohsaki Y, Shibata K, Yonei T, Hayashibara K, Fukushima M, Kawahara M, Furuse K, Mack PC: Serum osteopontin levels are highly prognostic for survival in advanced nonsmall cell lung cancer: results from JMTO LC 0004. J Thorac Oncol 2009, 4:1104-1110.
11. Vordermark D, Said HM, Katzer A, Kuhnt T, Hänsgen G, Dunst J, Flentje M, Bache M: Plasma osteopontin levels in patients with head and neck cancer and cervix cancer are critically dependent on the choice of ELISA system. BMC Cancer 2006, 6:207.
12. Le QT, Kong C, Lavori PW, O'Byrne K, Erler JT, Huang X, Chen Y, Cao H, Tibshirani R, Denko N, Giaccia AJ, Koong AC: Expression and prognostic significance of a panel of tissue hypoxia markers in head-and-neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 2007, 69:167-175.
13. Overgaard J, Eriksen JG, Nordsmark M, Alsner J, Horsman MR, Danish Head and Neck Cancer Study Group: Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol 2005, 6:757-764.
14. Blasberg JD, Pass HI, Goparaju CM, Flores R, Lee S, Donington JS: Reduction of elevated plasma osteopontin levels with resection of non-small-cell lung cancer. J Clin Oncol 2010, 28:936-941.
15. Ostheimer C, Bache M, Güttler A, Kotzsch M, Vordermark D: A pilot study on potential plasma hypoxia markers in the radiotherapy of non-small cell lung cancer: Osteopontin, carbonic anhydrase IX and vascular endothelial growth factor. Strahlenther Onkol 2013, Dec 11 [Epub ahead of print].
16. Wheatley-Price P, Yang B, Patsios D, Patel D, Ma C, Xu W, Leighl N, Feld R, Cho BC, O'Sullivan B, Roberts H, Tsao MS, Tammemagi M, Anraku M, Chen Z, de Perrot M, Lui G: Soluble mesothelin-related peptide and osteopontin as markers of response in malignant mesothelioma. J Clin Oncol 2010, 28:3316-3322.
17. Fedarko NS, Jain A, Karadag A, van Emam MR, Fisher LW: Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 2001, 7:4060-4066.
18. Donati V, Boldrini L, Dell'Omodarme M, Prati MC, Faviana P, Camacci T, Lucchi M, Mussi A, Santoro M, Basolo E, Fontanini G: Osteopontin expression and prognostic significance in non-small cell lung cancer. Clin Cancer Res 2005, 11:6459-6465.
19. Chang YS, Kim HJ, Chang J, Ahn CM, Kim SK, Kim SK: Elevated circulating level of osteopontin is associated with advanced disease state of nonsmall cell lung cancer. Lung Cancer 2007, 57:373-380.
20. Hu Z, Lin D, Yuan Y, Xiao T, Zhang H, Sun W, Han N, Ma Y, Di X, Gao M, Ma J, Zhang J, Cheng S, Gao Y: Overexpression of osteopontin is associated with more aggressive phenotypes in human non-small cell lung cancer. Clin Cancer Res 2005, 11:4646-4652.
21. Weber GF, Lett GS, Haubein NC: Osteopontin is a marker for cancer aggressiveness and patient survival. Br J Cancer 2010, 103:861-869.
22. Mountzios G, Ramfidis V, Terpos E, Syrigos KN: Prognostic significance of bone markers in patients with lung cancer metastatic to the skeleton: a review of published data. Clin Lung Cancer 2011, [Epub ahead of print].
23. Wai PY, Kuo PC: The role of Osteopontin in tumor metastasis. J Surg Res 2004, 121:228-241.
24. Singhal H, Bautista DS, Tonkin KS, O'Malley FP, Tuck AB, Chambers AF, Harris JF: Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 1997, 3:605-611.
25. Snitcovsky I, Leitao GM, Pasini FS, Brunialti KC, Mangone FR, Maistro S, de Castro JR, Villar RC, Federico MH: Plasma osteopontin levels in patients with head and neck cancer undergoing chemoradiotherapy. Arch Otolaryngol Head Neck Surg 2009, 135:807-811.
26. Mack PC, Redman MW, Chansky K, Williamson SK, Farneth NC, Lara PN Jr, Franklin WA, Le QT, Crowley JJ, Gandara DR, SWOG: Lower osteopontin plasma levels are associated with superior outcomes in advanced nonsmall- cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003. J Clin Oncol 2008, 26:4771-4776.
27. Petrik D, Lavori PW, Cao H, Zhu Y, Wong P, Christofferson E, Kaplan MJ, Pinto HA, Sutphin P, Koong AC, Giaccia AJ, Le QT: Plasma osteopontin is an independent prognostic marker for head and neck cancers. J Clin Oncol 2006, 24:5291-5297.
28. Baisi A, Raveglia F, De Simone M, Cioffi U: Micrometastasis and skip metastasis as predictive factors in no small-cell lung cancer staging. Eur J Cardiothorac Surg 2013, 5:1075 [Epub 2012].
29. Dehing-Oberije C, Aerts H, Yu S, De Ruysscher D, Menheere P, Hilvo M, van der Weide H, Rao B, Lambin P: Development and validation of a prognostic model using blood biomarker information for prediction of survival of non-small-cell lung cancer patients treated with combined chemotherapy and radiation or radiotherapy alone (NCT00181519, NCT00573040, and NCT00572325). Int J Radiat Oncol Biol Phys 2011, 81:360-368.
30. Mayer A, Höckel M, Vaupel P: Endogenous hypoxia markers: case not proven! Adv Exp Med Biol 2008, 614:127-136.
31. Zips D, Zöphel K, Abolmaali N, Perrin R, Abramyuk A, Haase R, Appold S, Steinbach J, Kotzerke J, Baumann M: Exploratory prospective trial of hypoxia-specific PET-imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer. Radiother Oncol 2012, 105:21-28.
32. Erpolat, Gocun PO, Akmansu M, Ozgun G, Akyol G: Hypoxia-related molecules HIF-1a, CA9, and osteopontin. Predictors of survival in patients with high-grade glioma. Strahlenther Onkol 2013, 189:147-154.
33. Gillham C, Zips D, Pönisch F, Evers C, Enghardt W, Abolmaali N, Zöphel K, Appold S, Hölscher T, Steinbach J, Kotzerke J, Herrmann T, Baumann M: Additional PET/CT in week 5-6 radiotheraoy for patients with stage III no small cell lung cancer as a means of dose escalation planning? Radiother Oncol 2008, 88:335-341.
34. Bramwell VHC, Gordon SD, Tuck AB, Wilson SM, Tonkin KS, Tomiak A, Perera E, Vandenberg TA, Chambers AF: Serial plasma osteopontin levels have prognostic value in metastatic breast cancer. Clin Cancer Res 2006, 12:3337-3343.